ReviewProblemy endokrinologii2024
[Arterial mediacalcinosis in patients with diabetes mellitus: etiopathogenetic and histopathological aspects].
Review in Problemy endokrinologii, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In a review of the generalized results of foreign and domestic studies on the development mechanism and pathogenesis of vascular calcification. The etiopathogenetic, pathophysiological and histomorphological features of mediacalcinosis, which reveal changes in the vascular bed in patients with DM, are considered. The role of risk factors for diseases, such as increased glycemia, changes in insulin levels, impaired lipid metabolism, obesity, arterial hypertension, CKD and aging, is indicated. The role of procalcifying and anticalcifying factors in colonic vascular remodeling is discussed. Identification of informative molecular markers and factors of CS will allow in the future to develop effective strategies for drug management of the risk of their progression and individual prevention programs to improve the quality and life expectancy in patients with cardiovascular diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.